PTCy预防后慢性GVHD特征与结局的单中心回顾研究
单中心回顾1534例成人移植受者,比较PTCy与非PTCy预防后慢性GVHD。PTCy组NIH中重度慢性GVHD累积发生率显著更低(17% vs 46%,P<.001),但24个月NRM更高(22% vs 13%,P=.014);多因素校正后慢性GVHD诊断后死亡率与非PTCy相当。
要点
- PTCy预防者NIH中重度慢性GVHD累积发生率17%,低于非PTCy的46%。
- PTCy组慢性GVHD累及器官少、严重度评分低,但未转化为生存获益。
- PTCy组24个月NRM为22%,高于非PTCy的13%(P=.014)。
核心结论
- PTCy预防降低慢性GVHD发生率与严重度,校正预后因素后慢性GVHD诊断后死亡率与非PTCy相当。
研究设计与样本
- 单中心回顾性研究纳入1534例连续成人移植受者,PTCy组477例、非PTCy组1057例,移植物来自相合同胞或相合/不全相合无关供者。
主要发现
- PTCy组与非PTCy组NIH中重度慢性GVHD累积发生率分别为17%与46%(P<.001)。
- 慢性GVHD患者中,PTCy组163例、非PTCy组656例,PTCy后慢性GVHD累及器官部位更少、严重度评分更低、NIH中重度比例更低。
- 单因素分析示PTCy组24个月NRM为22%,非PTCy组为13%(P=.014)。
- 多因素分析示NRM与年龄增加、NIH总体中重度慢性GVHD、既往III/IV级急性GVHD、血小板减少及胆红素升高相关。
- PTCy后慢性GVHD虽免疫抑制治疗减少且完全停用比例更高,但感染并发症增加。
临床怎么用
- PTCy预防可减少中重度慢性GVHD负担,但需关注NRM与感染并发症,尤其高龄、既往重度急性GVHD、血小板减少或胆红素升高者。
局限性
- 单中心回顾性设计,结果需多中心验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic graft-versus-host disease (GVHD) is less frequent after posttransplant cyclophosphamide (PTCy)-based prophylaxis, but its clinical characteristics and outcomes compared with chronic GVHD after non-PTCy approaches remain understudied. We addressed this through a single-center retrospective study of 1534 consecutive adult transplant recipients (PTCy, n = 477; non-PTCy, n = 1057) who received grafts from matched related or matched/mismatched unrelated donors. The cumulative incidence of National Institutes of Health (NIH) moderate/severe chronic GVHD was significantly lower after PTCy (17% vs 46%; P< .001). Among patients with chronic GVHD (PTCy, n = 163; non-PTCy, n = 656), chronic GVHD after PTCy involved fewer organ sites, had lower severity scores, and had less NIH moderate/severe disease overall. However, this profile did not translate into improved survival. Univariate analysis demonstrated higher nonrelapse mortality (NRM; 24-month NRM, 22% vs 13%; P = .014) for the PTCy group, whereas multivariate analysis showed that NRM was associated with increased age, NIH overall moderate/severe chronic GVHD severity, prior grade III/IV acute GVHD, reduced platelet count, and increased bilirubin. Chronic GVHD after PTCy was associated with increased infectious complications despite reduced immunosuppressive (IS) therapy and higher rates of complete IS discontinuation. Overall, PTCy-based prophylaxis was associated with a lower incidence and severity of chronic GVHD, and after adjustment for established prognostic factors, mortality after chronic GVHD diagnosis was comparable to that observed with non-PTCy prophylaxis approaches. Multicenter validation of these findings and novel strategies to mitigate NRM in chronic GVHD are warranted.
引用
- Pidala J, Kim J, Laborde J, et al. Chronic graft-versus-host disease after PTCy-based prophylaxis vs non-PTCy prophylaxis. Blood Adv. 2026. PMID: 42480215. doi:10.1182/bloodadvances.2026020655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。